Ad is loading...
ERAS
Price
$2.99
Change
+$0.09 (+3.10%)
Updated
Dec 6, 04:09 PM (EDT)
104 days until earnings call
KYMR
Price
$46.91
Change
+$2.82 (+6.40%)
Updated
Dec 6, 04:19 PM (EDT)
76 days until earnings call
Ad is loading...

ERAS vs KYMR

Header iconERAS vs KYMR Comparison
Open Charts ERAS vs KYMRBanner chart's image
Erasca
Price$2.99
Change+$0.09 (+3.10%)
Volume$100
CapitalizationN/A
Kymera Therapeutics
Price$46.91
Change+$2.82 (+6.40%)
Volume$300
CapitalizationN/A
ERAS vs KYMR Comparison Chart
Loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
KYMR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ERAS vs. KYMR commentary
Dec 07, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERAS is a Hold and KYMR is a Buy.

COMPARISON
Comparison
Dec 07, 2024
Stock price -- (ERAS: $2.90 vs. KYMR: $44.08)
Brand notoriety: ERAS and KYMR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERAS: 59% vs. KYMR: 70%
Market capitalization -- ERAS: $819.91M vs. KYMR: $2.85B
ERAS [@Biotechnology] is valued at $819.91M. KYMR’s [@Biotechnology] market capitalization is $2.85B. The market cap for tickers in the [@Biotechnology] industry ranges from $489.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.71B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERAS’s FA Score shows that 1 FA rating(s) are green whileKYMR’s FA Score has 0 green FA rating(s).

  • ERAS’s FA Score: 1 green, 4 red.
  • KYMR’s FA Score: 0 green, 5 red.
According to our system of comparison, ERAS is a better buy in the long-term than KYMR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERAS’s TA Score shows that 6 TA indicator(s) are bullish while KYMR’s TA Score has 5 bullish TA indicator(s).

  • ERAS’s TA Score: 6 bullish, 4 bearish.
  • KYMR’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than KYMR.

Price Growth

ERAS (@Biotechnology) experienced а -0.68% price change this week, while KYMR (@Biotechnology) price change was -5.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.41%. For the same industry, the average monthly price growth was -1.11%, and the average quarterly price growth was +12.54%.

Reported Earning Dates

ERAS is expected to report earnings on Mar 20, 2025.

KYMR is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Biotechnology (+0.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KYMR($2.86B) has a higher market cap than ERAS($820M). KYMR YTD gains are higher at: 73.134 vs. ERAS (36.150). ERAS has higher annual earnings (EBITDA): -151.33M vs. KYMR (-160.96M). KYMR has more cash in the bank: 550M vs. ERAS (319M). ERAS has less debt than KYMR: ERAS (52.9M) vs KYMR (88.2M). KYMR has higher revenues than ERAS: KYMR (87.6M) vs ERAS (0).
ERASKYMRERAS / KYMR
Capitalization820M2.86B29%
EBITDA-151.33M-160.96M94%
Gain YTD36.15073.13449%
P/E RatioN/AN/A-
Revenue087.6M-
Total Cash319M550M58%
Total Debt52.9M88.2M60%
TECHNICAL ANALYSIS
Technical Analysis
ERASKYMR
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 10 days ago
79%
Bullish Trend 12 days ago
85%
Declines
ODDS (%)
Bearish Trend 16 days ago
86%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
75%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
View a ticker or compare two or three
Ad is loading...
ERAS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
KYMR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ICEWX39.310.24
+0.61%
NYLI Epoch International Choice Class C
RMMTX16.750.02
+0.12%
Russell Inv Emerging Markets M
UTPIX75.65N/A
N/A
ProFunds Utilities UltraSector Inv
KGGIX12.25N/A
N/A
Kopernik Global All-Cap I
FTHFX49.50-3.88
-7.27%
FullerThaler Behavioral Sm-Cp Eq R6

ERAS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERAS has been loosely correlated with XNCR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ERAS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERAS
1D Price
Change %
ERAS100%
-7.35%
XNCR - ERAS
48%
Loosely correlated
-3.36%
KYMR - ERAS
46%
Loosely correlated
-4.22%
BEAM - ERAS
45%
Loosely correlated
-2.69%
PLRX - ERAS
44%
Loosely correlated
-2.86%
RCKT - ERAS
44%
Loosely correlated
-1.91%
More

KYMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, KYMR has been loosely correlated with RXRX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if KYMR jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KYMR
1D Price
Change %
KYMR100%
-4.22%
RXRX - KYMR
47%
Loosely correlated
-7.57%
KROS - KYMR
46%
Loosely correlated
-4.69%
PRTA - KYMR
46%
Loosely correlated
-4.13%
ACLX - KYMR
45%
Loosely correlated
+0.66%
OMGA - KYMR
45%
Loosely correlated
-5.25%
More